Sempértegui F, Estrella B, Camaniero V, Betancourt V, Izurieta R, Ortiz W, Fiallo E, Troya S, Rodríguez A, Griffiths J K
Corporación Ecuatoriana de Biotecnología (Ecuadorian Biotechnology Corporation), Escuela de Medicina, Universidad Central del Ecuador, Quito, Ecuador.
Pediatrics. 1999 Jul;104(1):e1. doi: 10.1542/peds.104.1.e1.
Previous studies of large-dose vitamin A supplementation on respiratory morbidity have produced conflicting results in a variety of populations. The influence of malnutrition has not been examined in the majority of these trials. We hypothesized that weekly low-dose vitamin A supplementation would prevent respiratory and diarrheal disease morbidity and that malnutrition might influence the efficacy of vitamin A supplementation.
In a randomized, double-blind, placebo-controlled field trial of 400 children, 6 to 36 months of age in a high Andean urban slum, half of the children received 10 000 IU of vitamin A weekly and half received placebo for 40 weeks. Children were visited weekly at home by physicians and assessed for acute diarrheal disease and acute respiratory infections.
Acute diarrheal disease and acute respiratory infection did not differ globally or by severity between supplement-treated and placebo groups. However, the incidence of acute lower respiratory infection (ALRI) was significantly lower in underweight (weight-for-age z score [WAZ] <-2 SD) supplement-treated children than in underweight children on placebo (8.5 vs 22.3 per 10(3) child-weeks; rate ratio: 0.38 [95% CI: 0.17-0.85]). ALRI incidence was significantly higher in normal-weight (WAZ >-2 SD) supplement-treated children than in normal-weight children on placebo (9.8 vs 4.4 per 10(3) child-weeks; rate ratio: 2.21 [95% CI: 1.24-3.93]). By logistic regression analysis the risk of ALRI was lower in underweight supplement-treated children than in underweight children on placebo (point estimate 0.148 [95% CI: 0.034-0.634]). In contrast, risk of ALRI was higher in normal-weight supplement-treated children (WAZ >-1 SD to mean) than in normal-weight children on placebo in the same WAZ stratum (point estimate: 2.51 [95% CI: 1.24-5.05]). The risk of severe diarrhea was lower in supplement-treated children 18 to 23 months of age than in children on placebo in this age group (point estimate: 0.26 [95% CI: 0.06-1.00]).
Weekly low-dose (10 000 IU) vitamin A supplementation in a region of subclinical deficiency protected underweight children from ALRI and paradoxically increased ALRI in normal children with body weight over -1 SD. Protection from severe diarrhea was consistent with previous trials. Additional research is warranted to delineate potential beneficial and detrimental interactions between nutritional status and vitamin A supplementation regarding ALRI.
先前关于大剂量补充维生素A对呼吸道疾病发病率影响的研究,在不同人群中得出了相互矛盾的结果。在大多数此类试验中,尚未考察营养不良的影响。我们假设每周低剂量补充维生素A可预防呼吸道和腹泻疾病的发病,且营养不良可能会影响维生素A补充的效果。
在一项针对安第斯山脉高处一个城市贫民窟中400名6至36个月大儿童的随机、双盲、安慰剂对照现场试验中,一半儿童每周接受10000国际单位的维生素A,另一半接受安慰剂,为期40周。医生每周上门探访儿童,评估其急性腹泻病和急性呼吸道感染情况。
补充剂治疗组和安慰剂组在急性腹泻病和急性呼吸道感染的总体情况或严重程度方面并无差异。然而,体重不足(年龄别体重Z评分[WAZ]<-2标准差)的补充剂治疗儿童的急性下呼吸道感染(ALRI)发病率显著低于接受安慰剂的体重不足儿童(每10³儿童周8.5例对22.3例;发病率比:0.38[95%置信区间:0.17 - 0.85])。体重正常(WAZ>-2标准差)的补充剂治疗儿童的ALRI发病率显著高于接受安慰剂的体重正常儿童(每10³儿童周9.8例对4.4例;发病率比:2.21[95%置信区间:1.24 - 3.93])。通过逻辑回归分析,体重不足的补充剂治疗儿童发生ALRI的风险低于接受安慰剂的体重不足儿童(点估计值0.148[95%置信区间:0.034 - 0.634])。相比之下,体重正常(WAZ>-1标准差至均值)的补充剂治疗儿童在相同WAZ分层中发生ALRI的风险高于接受安慰剂的体重正常儿童(点估计值:2.51[95%置信区间:1.24 - 5.05])。18至23个月大的补充剂治疗儿童发生严重腹泻的风险低于该年龄组接受安慰剂的儿童(点估计值:0.26[95%置信区间:0.06 - 1.00])。
在亚临床缺乏地区,每周低剂量(10000国际单位)补充维生素A可保护体重不足儿童免受ALRI影响,而对于体重超过 -1标准差的正常儿童,却反常地增加了ALRI的发病风险。预防严重腹泻与先前试验结果一致。有必要进行更多研究,以阐明营养状况与补充维生素A在ALRI方面潜在的有益和有害相互作用。